-
公开(公告)号：KR1020120095046A
公开(公告)日：2012-08-28
申请号：KR1020110014438
申请日：2011-02-18
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K38/20 , A61K48/005 , Y10S424/81
Abstract: PURPOSE: A composition for preventing or treating immunological rejection diseases including IL-27 is provided to alleviate the immunological rejection disease by suppressing rejection towards the host after the transplanted cell or organ is engrafted. CONSTITUTION: A composition for preventing or treating immunological rejection diseases includes IL-27 as an active component. The IL-27 has amino acid sequence described in the sequence number 1(SEQ ID NO:1). The composition for preventing or treating immunological rejection diseases includes a vector containing polynucleotide which codes the IL-27 as an active ingredient. The polynucleotide has the base sequence described in the sequence number 2. The immunological rejection disease is graft-versus-host disease.
Abstract translation: 目的：提供一种用于预防或治疗免疫排斥疾病（包括IL-27）的组合物，用于通过在移植的细胞或器官移植后抑制对宿主的排斥来减轻免疫排斥疾病。 构成：用于预防或治疗免疫排斥疾病的组合物包括IL-27作为活性成分。 IL-27具有序列号1（SEQ ID NO：1）中描述的氨基酸序列。 用于预防或治疗免疫排斥疾病的组合物包括编码IL-27作为活性成分的含有多核苷酸的载体。 多核苷酸具有序列号2中描述的碱基序列。免疫排斥疾病是移植物抗宿主病。
-
公开(公告)号：KR1020150000717A
公开(公告)日：2015-01-05
申请号：KR1020130073185
申请日：2013-06-25
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0783 , C12N5/02
Abstract: 본 발명은 덱사메타손, 비타민 D
3 , 및 TGF-β를 포함하는, 미분화 T 세포로부터 IL-10 생성 조절 T세포(IL-10 producing regulatory T cell)로의 분화 유도용 조성물 및 상기 조성물을 처리하여 미분화 T세포를 IL-10 생성 조절 T 세포로의 분화를 유도하는 방법에 관한 것이다.Abstract translation: 本发明涉及用于从未分化的T细胞（包括地塞米松，维生素D3和TGF-β）诱导产生IL-10的调节性T细胞的组合物，以及通过加工从未分化的T细胞诱导产生IL-10调节性T细胞的方法 组成。
-
23.发明授权
公开(公告)号：KR101432881B1
公开(公告)日：2014-08-21
申请号：KR1020120016400
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/203 , A61K31/07 , A61P29/00 , A61P35/00
Abstract: 본 발명은 레티날(retinal) 또는 레티노산(retinoic acid)을 유효성분으로 포함하는 세포보호용 조성물에 관한 것으로서, 보다 구체적으로 본 발명은 레티날 또는 레티노산을 유효성분으로 포함하는 자연살해세포의 세포독성 감소 또는 억제를 통한 세포보호용 조성물에 관한 것이다. 본 발명에 따른 레티날 및 레티노산이 첨가된 조절 T세포는 자연살해세포의 세포독성을 감소시키거나 억제하는 효과가 우수하여, 각종 면역반응의 조절 이상으로 유발되는 자가면역질환, 염증성질환 및 이식거부질환과 같은 면역질환을 예방 또는 치료할 수 있는 세포보호용 조성물로 유용하게 사용할 수 있다.
-
公开(公告)号：KR1020120118619A
公开(公告)日：2012-10-29
申请号：KR1020110036097
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C12Q1/02 , C12N5/0619 , C12N2506/025 , C12N2506/1346 , G01N27/62 , G01N33/5008 , G01N33/60 , G01N33/68 , G01N2333/78
Abstract: PURPOSE: A material screening method for promoting differentiation to the nerve cell of stem cell is provided to rapidly and efficiently detect materials which help signal transmission so that the stem cells can be differentiated into nerve cells. CONSTITUTION: A material screening method for promoting differentiation to the nerve cell of stem cell comprises the following steps: processing candidate materials for neural cell differentiation promotion in the stem cell; measuring the phosphorylation of the beta - catenin in the cells; and assorting the candidate materials which multiply the phosphorylation activity of the beta - catenin by comparing with the stem cells which is not processed with the candidate materials. The stem cell is the mesenchyme stem cell. The mesenchyme stem cell is human umbilical cord originated cell. The processing of the candidate material is the overexpression of the candidate material by transformation.
Abstract translation: 目的：提供促进干细胞神经细胞分化的材料筛选方法，快速有效地检测有助于信号传导的物质，使干细胞分化成神经细胞。 构成：促进干细胞神经细胞分化的材料筛选方法包括以下步骤：处理干细胞中神经细胞分化促进的候选物质; 测量细胞中β-连环蛋白的磷酸化; 并通过与未用候选材料处理的干细胞进行比较，分类增加β-连环蛋白的磷酸化活性的候选物质。 干细胞是间充质干细胞。 间质干细胞是人脐带起源细胞。 候选材料的处理是通过转型对候选材料的过度表达。
-
25.发明公开
公开(公告)号：KR1020120095320A
公开(公告)日：2012-08-28
申请号：KR1020120016400
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/203 , A61K31/07 , A61P29/00 , A61P35/00
Abstract: PURPOSE: A cytoprotection composition for toxicity suppression of natural killer cells including retinal or retinoic acid are provided to reduce or suppress toxicity of the natural killer cells by including T-cells. CONSTITUTION: A cytoprotection composition for toxicity suppression of natural killer cells includes retinal or retinoic acid as an active ingredient. The retinal or retinoic acid suppresses or prevent the cytotoxin of the natural killer cell as reduction. 0.1-5 microM of the retinal or retinoic acid is included. The cytoprotection composition for toxicity suppression of natural killer cells comprises T-cells which are differentiated by processing the retinal or the retinoic acid and human adipose derived mesenchymal stem cells. The differentiated Thymusdependentlymphocyte(treg cell) and the human adipose derived mesenchymal stem cells are included at a rate of 1:0.01-1:0.03.
Abstract translation: 目的：提供用于毒性抑制天然杀伤细胞（包括视网膜或视黄酸）的细胞保护组合物，以通过包括T细胞来减少或抑制天然杀伤细胞的毒性。 构成：用于毒性抑制天然杀伤细胞的细胞保护组合物包括视黄醛或视黄酸作为活性成分。 视网膜或视黄酸抑制或预防自然杀伤细胞的细胞毒素作为还原。 包括0.1-5微米的视网膜或视黄酸。 用于天然杀伤细胞毒性抑制的细胞保护组合物包括通过加工视网膜或视黄酸和人脂肪来源的间充质干细胞分化的T细胞。 分化的胸腺依赖性淋巴细胞（treg细胞）和人脂肪来源的间充质干细胞以1:0.01-1:0.03的比率包含。
-
Patent Agency Ranking
-
公开(公告)号：KR101867942B1
公开(公告)日：2018-06-20
申请号：KR1020160135707
申请日：2016-10-19
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/078 , A61K35/14 , C07K14/005 , C07K16/28
CPC classification number: C12N5/0636 , A61K35/17 , A61K39/235 , A61K2039/5156 , A61K2039/5158 , C07K14/005 , C07K16/246 , C07K16/28 , C12N2510/00 , C12N2710/10011 , C12N2710/16111 , Y02A50/467
Abstract: 본발명은표적바이러스항원에특이적인이중활성 T 세포및 CIK 세포의유도및 증식방법에관한것으로, 말초혈액에서분리한단핵구를사이토카인과바이러스항원펩타이드혼합물을함께처리하여배양함으로써표적바이러스항원에특이적인이중활성 T 세포및 CIK 세포를생산할수 있다.
-
28.发明授权간엽줄기세포 및 면역조절 T 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 有权用于预防或治疗包含间充质干细胞和免疫调节性T细胞作为活性成分的免疫疾病的T细胞疗法组合物
公开(公告)号：KR101578591B1
公开(公告)日：2015-12-17
申请号：KR1020137021403
申请日：2012-02-17
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K31/21 , A61K35/17 , A61K39/001 , A61K2039/5158 , C12N5/0637 , C12N5/0667 , C12N2501/15 , C12N2501/51 , C12N2501/515 , A61K2300/00
Abstract: 본발명은간엽줄기세포및 면역조절 T 세포를유효성분으로포함하는면역질환의예방또는치료용세포치료제조성물에관한것이다. 본발명의세포치료제인간엽줄기세포와면역조절 T 세포를골수이식동물에게적용하는경우, 이식된골수가생착된후 숙주에대한거부반응이억제됨으로써면역질환, 예컨대이식편대숙주질환을감소시키는효과를갖는다. 또한이러한면역질환증상의감소수치는, 간엽줄기세포를단독을처리한경우와비교하여월등히향상된효과를가진다. 따라서상기와같은효과를갖는본 발명의세포치료제조성물은면역질환의예방또는치료에서유용하게사용될수 있다.
-
29.发明公开자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물 有权细胞治疗组合物，用于预防或治疗包含NK细胞抑制剂和中胚层干细胞的遗传病
公开(公告)号：KR1020130023797A
公开(公告)日：2013-03-08
申请号：KR1020110086819
申请日：2011-08-30
Applicant: 가톨릭대학교 산학협력단
IPC: A61K39/395 , A61K35/28 , A61K9/00
CPC classification number: A61K39/395 , A61K9/0019 , A61K35/28
Abstract: PURPOSE: A cell therapeutic composition containing a natural killer cell inhibitor and mesenchymal stem cells is provided to effectively suppress immune rejection responses, and to enhance a treatment effect. CONSTITUTION: A cell therapeutic composition for preventing or treating graft-versus-host diseases contains 2.5mg/kg-250mg/kg of a natural killer cell inhibitor and 2x10^5-2x10^7 mesenchymal stem cells as active ingredients. The mesenchymal stem cells are derived from human. The inhibitor is anti-asialo GM1. The composition contains is administered by intravenous or intradural injection.
Abstract translation: 目的：提供含有天然杀伤细胞抑制剂和间充质干细胞的细胞治疗组合物，以有效抑制免疫排斥反应，提高治疗效果。 构成：用于预防或治疗移植物抗宿主病的细胞治疗组合物含有2.5mg / kg-250mg / kg的天然杀伤细胞抑制剂和2x10 ^ 5-2x10 ^ 7间充质干细胞作为活性成分。 间充质干细胞来源于人。 抑制剂为抗脱唾液酸GM1。 组合物含有通过静脉内或硬膜外注射施用。
-
公开(公告)号：KR101865040B1
公开(公告)日：2018-06-11
申请号：KR1020170001943
申请日：2017-01-05
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0775 , A61K35/28 , A61K38/21 , A61K38/19
CPC classification number: C12N5/0662 , A61K35/28 , A61K38/191 , A61K38/215 , A61K38/217 , C12N2501/231 , C12N2501/24 , C12N2501/25
Abstract: 본발명은사이토카인을처리한중간엽줄기세포, 사이토카인처리에따른중간엽줄기세포의염증조절인자생성능을강화시키는방법및 상기염증조절인자생성능이강화된중간엽줄기세포를유효성분으로포함하는면역질환및 염증성질환의예방, 치료용조성물에관한것으로, 중간엽줄기세포배양시세 가지또는네 가지의사이토카인을낮은농도로처리하여염증조절인자의생성능이강화된중간엽줄기세포를제공함으로써, COX-2, IDO 등의염증조절인자의생성을극대화시켜면역질환및 염증성질환에대한치료효과를나타낼수 있다.
-
-
-
-
-
-
-
-
-
Search Results
34
records
(took 0.035 seconds)
